Novartis Hellas company information, Employees & Contact Information

FDA approves Novartis radioligand therapy Pluvicto® for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer Novartis

Novartis continues strong momentum of sales growth with margin expansion, reaches key innovation milestones in 2024 Novartis

Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline Novartis

Novartis Tafinlar® (dabrafenib) + Mekinist® (trametinib) demonstrates unprecedented efficacy in pediatric patients with BRAF V600 low-grade gliomas in Phase II/III study Novartis

Research and development Novartis

Novartis Tafinlar + Mekinist approved by FDA for pediatric patients with BRAF V600E low-grade glioma, the most common pediatric brain cancer Novartis

Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront Novartis

Global Health disease area research at Novartis Novartis

Immunology disease research at Novartis Novartis

New Novartis Phase III data demonstrate meaningful efficacy and safety results of intrathecal onasemnogene abeparvovec in broad patient population with SMA Novartis

Novartis Scemblix® Phase III data first to show superior efficacy with a favorable safety and tolerability profile vs. standard-of-care TKIs in adults with newly diagnosed CML Novartis

People and culture Novartis

Sickle cell disease Novartis

Novartis Kisqali® shows deepening benefit in new analysis, reducing the risk of recurrence by 28.5% in a broad population of patients with early breast cancer Novartis

Community exploration and learning lab (CELL) Novartis

Novartis enters agreement to acquire Mariana Oncology, strengthening radioligand therapy pipeline Novartis

Climate Novartis

Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer Novartis

Novartis bolsters innovative medicines strategy and renal pipeline with agreement to acquire Chinook Therapeutics for USD 3.2bn upfront (USD 40 / share) Novartis

Novartis ribociclib (Kisqali®) recognized as Category 1 preferred breast cancer adjuvant treatment by NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Novartis

FDA approves Novartis Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma Novartis

Novartis announces intention to separate Sandoz business to create a standalone company by way of a 100% spin-off Novartis

About Novartis

Novartis announces tislelizumab demonstrated efficacy and tolerability in first-line advanced liver cancer in Phase III trial Novartis

Novartis receives European Commission approval for Pluvicto® as the first targeted radioligand therapy for treatment of progressive PSMA–positive metastatic castration-resistant prostate cancer Novartis

Novartis Kisqali® NATALEE analysis reinforces consistent reduction in risk of recurrence across key subgroups of patients with early breast cancer Novartis

Novartis receives positive CHMP opinion for Pluvicto® for patients with progressive, PSMA-positive metastatic castration-resistant prostate cancer Novartis

Novartis Pluvicto™ shows statistically significant and clinically meaningful radiographic progression-free survival benefit in patients with PSMA–positive metastatic castration-resistant prostate cancer Novartis

Novartis confirms Sandoz Spin-off for October 4, 2023 Novartis

Novartis announces planned acquisition of Endocyte to expand expertise in radiopharmaceuticals and build on commitment to transformational therapeutic platforms Novartis

Novartis JULIET trial of Kymriah demonstrates more than one-year durability of responses in adults with relapsed or refractory DLBCL Novartis

Novartis ALK+ metastatic NSCLC therapy Zykadia® extends progression-free survival beyond 18 months in Phase II study Novartis

Novartis announces positive result of phase III study with radioligand therapy 177Lu-PSMA-617 in patients with advanced prostate cancer Novartis

Advanced Accelerator Applications Receives FDA Approval for Lutathera® for Treatment of Gastroenteropancreatic Neuroendocrine Tumors Novartis

Novartis drug Afinitor® recommended by CHMP for European Union approval to treat select GI and lung neuroendocrine tumors Novartis

Product sales Novartis

Novartis Kymriah® demonstrates consistent efficacy and safety outcomes in US patients when used in real-world setting Novartis

Novartis drug Tasigna® approved by FDA to treat children with rare form of leukemia Novartis

Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah(TM) (CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice Novartis

Novartis announces longer-term analyses from pivotal Kymriah® trials that showed durable responses are maintained in patients with advanced blood cancers Novartis

Novartis Kymriah® pivotal trial demonstrates strong response rates and a remarkable safety profile in relapsed or refractory follicular lymphoma Novartis

Kymriah® (tisagenlecleucel), first-in-class CAR-T therapy from Novartis, receives second FDA approval to treat appropriate r/r patients with large B-cell lymphoma Novartis

Novartis continues to innovate in CML with long-term treatment-free remission results following Tasigna® use and promising combination data with investigational compound asciminib (ABL001) Novartis

Novartis Kymriah® receives EC approval as first CAR-T cell therapy for adults with relapsed or refractory follicular lymphoma Novartis

Novartis' targeted cancer drug combo goes tumor-agnostic with new FDA approval Fierce Pharma

Novartis receives EU approval for first-line use of Zykadia® in ALK-positive advanced non-small cell lung cancer (NSCLC) Novartis

Novartis receives European Commission approval of its CAR-T cell therapy, Kymriah® (tisagenlecleucel) Novartis

Novartis presents new data from large European study reinforcing the benefit of first-line Tasigna® in newly-diagnosed patients with CML Novartis

Novartis drug Afinitor® significantly reduces seizures in Phase III study of patients with tuberous sclerosis complex Novartis

Novartis announces NEJM publication of updated analysis from ELIANA trial showing longer-term durable remissions with Kymriah(TM) in children, young adults with r/r ALL Novartis

Novartis drug Votubia® receives EU approval to treat refractory partial-onset seizures in patients with TSC Novartis

Novartis pivotal CTL019 6-month follow-up data show durable remission rates in children, young adults with r/r B-cell ALL Novartis

Novartis chief’s 2018 take-home pay suffers—not from Cohen but from low-grade returns Fierce Pharma

Novartis drug Afinitor® receives EU approval to treat certain types of advanced gastrointestinal (GI) and lung neuroendocrine tumors (NET) Novartis

Novartis’ Lutathera Radiopharma Therapy Improves Survival in Difficult-to-Treat Brain Tumors BioSpace

Greece Drops Anonymity for Novartis Case Whistleblowers Organized Crime and Corruption Reporting Project | OCCRP

Novartis case still ground for political fights eKathimerini.com

Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials The New England Journal of Medicine